Taku Kobayashi

9.5k citations

161 papers · 5.3k indexed · 3 hit papers · h-index 36

Genetics top 0.5%
- Inflammatory Bowel Disease 118
Immunology top 1%
Gastroenterology top 1%
- Celiac Disease Research and Management 10
Epidemiology top 2%
- Microscopic Colitis 78
- Mycobacterium research and diagnosis 10
- Autoimmune and Inflammatory Disorders 8
Pharmacology top 2%
Surgery
- Eosinophilic Esophagitis 16
- Helicobacter pylori-related gastroenterology studies 14
Oncology
- Colorectal Cancer Screening and Detection 10

Co-authors: Toshifumi Hibi∥Silvio Danese Laurent Peyrin‐Biroulet Tadakazu Hisamatsu Britta Siegmund Bo Shen Catherine Le Berre Charles N. Bernstein
Cited by: Genetics Immunology Gastroenterology
Journals: New England Journal of Medicine (1 paper)Journal of Biological Chemistry (1 paper)Journal of Clinical Investigation (1 paper)
Partner nations: Japan United States Canada

In The Last Decade

Taku Kobayashi

141 papers receiving 5.2k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2023 New England Journal of Medicine
2020 Nature Reviews Disease Primers
2019 Gastroenterology

Peers

Countries citing papers authored by Taku Kobayashi

Since Specialization

Citations

This map shows the geographic impact of Taku Kobayashi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Taku Kobayashi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Taku Kobayashi more than expected).

Fields of papers citing papers by Taku Kobayashi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Taku Kobayashi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Taku Kobayashi. The network helps show where Taku Kobayashi may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Taku Kobayashi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Taku Kobayashi Line = papers co-authored together Taku Kobayashi links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Optimising carotegrast methyl use in ulcerative colitis: patient profiling, predictive biomarkers, and timing of efficacy evaluation (ASPECT study) Journal of Gastroenterology ·Katsuyoshi Matsuoka,Fumihito Hirai,Kenji Watanabe,Ryota Hokari,Taku Kobayashi,Masayuki Saruta,Hiroshi Nakase,Takahiro Suzuki,G Yamazaki,Toshifumi Hibi,Mamoru Watanabe,Tadakazu Hisamatsu	2025	0
2	Real‐World Effectiveness and Safety of Mirikizumab Induction Therapy in Patients With Ulcerative Colitis: A Multicentre Retrospective Observational Study Alimentary Pharmacology & Therapeutics ·Yasuhiro Takagi,Toshiyuki Sato,Takanori Nishiguchi,Akira Nogami,Masataka Igeta,Soichi Yagi,Maiko Ikenouchi,Mikio Kawai,Koji Kamikozuru,Yoko Yokoyama,Toshihiko Tomita,Hirokazu Fukui,Masayuki Fukata,Taku Kobayashi,Shinichiro Shinzaki	2025	4
3	Propensity score-matched real-world comparative treatment outcomes of Janus kinase inhibitors for ulcerative colitis in patients with and without prior exposure to anti-tumor necrosis factor α antibody Intestinal Research ·Maiko Ikenouchi,Hirokazu Fukui,Soichi Yagi,Akira Nogami,Koji Kaku,Toshiyuki Sato,Mikio Kawai,Koji Kamikozuru,Yukio Yokoyama,Tetsuya Takagawa,Toshihiko Tomita,Taku Kobayashi,Shinichiro Shinzaki	2025	0
4	Fecal Calprotectin and C-Reactive Protein Association With Histologic and Endoscopic Endpoints in Mirikizumab-Treated Patients With Ulcerative Colitis Crohn s & Colitis 360 ·Remo Panaccione,Faye Chan-Diehl,Simin Baygani,Deborah A. Fisher,Richard Moses,Britta Siegmund,Alissa Walsh,Taku Kobayashi,Parambir S. Dulai,Simon Travis	2025	1
5	Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn’s disease and ulcerative colitis Journal of Crohn s and Colitis ·Geert D’Haens,Silvio Danese,Remo Panaccione,David T. Rubin,Laurent Peyrin‐Biroulet,Katsuyoshi Matsuoka,Edward V. Loftus,Taku Kobayashi,Walid Elsharkawi,Rosa Miceli,Samia A. Ahmed,Yi Luo,Andrew Napoli,John Vaile,Quentin Dornic,Aditya Patel,Stefan Schreiber	2025	0
6	Early resolution of bowel urgency by budesonide foam enema results in improved quality of life in patients with ulcerative colitis: a multicenter prospective observational study Intestinal Research ·Taku Kobayashi,Kei Moriya,Toshimitsu Fujii,Shigeki Bamba,Shinichiro Shinzaki,Akihiro Yamada,Takashi Hisabe,Shintaro Sagami,Shuji Hibiya,Takahiro Amano,Noritaka Takatsu,Katsutoshi Inagaki,K Iwayama,Toshifumi Hibi∥	2024	0
7	Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study Inflammatory Bowel Diseases ·Bruce E. Sands,Geert D’Haens,David B. Clemow,Peter M. Irving,Jordan Johns,Theresa Hunter Gibble,Maria T. Abreu,Scott D. Lee,Tadakazu Hisamatsu,Taku Kobayashi,Marla C. Dubinsky,Séverine Vermeire,Corey A. Siegel,Laurent Peyrin-Biroulet,Richard Moses,Joe Milata,Remo Panaccione,Axel Dignaß	2024	14
8	Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study Inflammatory Bowel Diseases ·Bruce E. Sands,Geert D’Haens,David B. Clemow,Peter M. Irving,Jordan Johns,Theresa Hunter,María T. Abreu,Scott D. Lee,Tadakazu Hisamatsu,Taku Kobayashi,Marla C. Dubinsky,Séverine Vermeire,Corey A. Siegel,Laurent Peyrin‐Biroulet,Richard Moses,Joe Milata,Vipin Arora,Remo Panaccione,Axel Dignaß	2024	26
9	Real‐World Comparative Effectiveness and Safety of Filgotinib and Upadacitinib for Ulcerative Colitis: A Multicentre Cohort Study United European Gastroenterology Journal ·Akira Nogami,Kunio Asonuma,Shinji Okabayashi,Maiko Ikenouchi,Takahisa Matsuda,Shinichiro Shinzaki,Masayuki Fukata,Taku Kobayashi	2024	2
10	Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies Intestinal Research ·Taku Kobayashi,Katsuyoshi Matsuoka,Mamoru Watanabe,Tadakazu Hisamatsu,Fumihito Hirai,Joe Milata,Xingyuan Li,Nathan Morris,Vipin Arora,Tomoko Ishizuka,Koji Matsuo,Yoichi Satoi,Catherine Milch,Toshifumi Hibi∥	2024	5
11	Improving IBD outcomes in the era of many treatment options Nature Reviews Gastroenterology & Hepatology ·Taku Kobayashi,Toshifumi Hibi∥	2023	50
12	Immunomodulators after the discontinuation of anti‐tumor necrosis factor‐alpha antibody treatment and relapse in ulcerative colitis: A multicenter cohort study Journal of Gastroenterology and Hepatology ·Kunio Asonuma,Keiji Ozeki,Hajime Yamazaki,Shinji Okabayashi,Soh Okano,Ryo Ozaki,Nobuaki Nishimata,Hiroki Kiyohara,Naoki Ichinari,Taku Kobayashi,Masahiro Yamada,Mao Matsubayashi,Yoko Yokoyama,Shoko Arimitsu,Junji Umeno,Yoshinori Munetomo,Akira Andoh,Shinichiro Shinzaki,(unknown)	2023	1
13	Artificial intelligence quantifying endoscopic severity of ulcerative colitis in gradation scale Digestive Endoscopy ·Kaoru Takabayashi,Taku Kobayashi,Katsuyoshi Matsuoka,Barrett G. Levesque,Takuji Kawamura,Kiyohito Tanaka,T Kadota,Ryoma Bise,Seiichi Uchida,Takanori Kanai∥,Haruhiko Ogata	2023	17
14	iSTART-II: An Update on the i Support Therapy–Access to Rapid Treatment (iSTART) Approach for Patient-Centered Therapy in Mild-to-Moderate Ulcerative Colitis Journal of Clinical Medicine ·Ferdinando D’Amico,Fernando Magro,Bénédicte Caron,Axel Dignaß,Vipul Jairath,Ailsa Hart,Paulo Gustavo Kotze,Kristine Paridaens,Sameer Al Awadhi,Taku Kobayashi,Britta Siegmund,Laurent Peyrin‐Biroulet,Silvio Danese	2023	2
15	Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes Journal of Crohn s and Colitis ·Fernando Magro,Rish K. Pai,Taku Kobayashi,Vipul Jairath,Florian Rieder,Isabel Redondo,Trevor Lissoos,Nathan Morris,Mingyang Shan,Meekyong Park,Laurent Peyrin‐Biroulet	2023	27
16	Early-Phase Partial Mayo Score following Golimumab Treatment Is Associated with Endoscopic Improvement at 1 Year in Ulcerative Colitis: A post hoc Analysis of PURSUIT-J Randomized Controlled Trial Inflammatory Intestinal Diseases ·Katsumasa Nagano,Yuya Imai,Yoshifumi Ukyo,Taku Kobayashi,Seiji Yokoyama	2022	2
17	Lower effectiveness of intravenous steroid treatment for moderate‐to‐severe ulcerative colitis in hospitalised patients with older onset: a multicentre cohort study Alimentary Pharmacology & Therapeutics ·Shinji Okabayashi,Hajime Yamazaki,Keiichi Tominaga,Miki Miura,Shintaro Sagami,Katsuyoshi Matsuoka,Yoshiharu Yamaguchi,Toshihiro Noake,Keiji Ozeki,Ryosuke Miyazaki,Toshiaki Kamano,T. Fukuda,Kyoko Yoshioka,Katsuyoshi Ando,Masakatsu Fukuzawa,Akira Andoh,Yosuke Yamamoto,Toshifumi Hibi∥,Taku Kobayashi,(unknown)	2022	8
18	Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis Intestinal Research ·Taku Kobayashi,Hiroaki Ito,Toshifumi Ashida,Tadashi Yokoyama,Masakazu Nagahori,Tomoki Inaba,Mitsuhiro Shikamura,Takayoshi Yamaguchi,Tetsuharu Hori,Philippe Pinton,Mamoru Watanabe,Toshifumi Hibi∥	2020	10
19	Management of Primary Nonresponders and Partial Responders to Tumor Necrosis Factor-α Inhibitor Induction Therapy among Patients with Crohn’s Disease Inflammatory Intestinal Diseases ·Hideki Iijima,Taku Kobayashi,Mitsuo Nagasaka,Shinichiro Shinzaki,Kazuya Kitamura,Yasuo Suzuki,Mamoru Watanabe,Toshifumi Hibi∥,(unknown)	2020	5
20	Lectin-based Immunoassay for Aberrant IgG Glycosylation as the Biomarker for Crohnʼs Disease Inflammatory Bowel Diseases ·Shinichiro Shinzaki,Eri Kuroki,Hideki Iijima,Norika Tatsunaka,Mayuko Ishii,Hironobu Fujii,Yoshihiro Kamada,Taku Kobayashi,Narihiro Shibukawa,Takahiro Inoue,Masahiko Tsujii,Shunsaku Takeishi,Tsunekazu Mizushima,Atsushi Ogata,Tetsuji Naka,Scott E. Plevy,Tetsuo Takehara,Eiji Miyoshi	2012	36

About Taku Kobayashi

Taku Kobayashi is a scholar working on Genetics, Gastroenterology and Epidemiology, having authored 161 papers that have together received 5.3k indexed citations. Recurring topics across this work include Inflammatory Bowel Disease (118 papers), Microscopic Colitis (78 papers), Eosinophilic Esophagitis (16 papers), Helicobacter pylori-related gastroenterology studies (14 papers), Colorectal Cancer Screening and Detection (10 papers), Mycobacterium research and diagnosis (10 papers), Celiac Disease Research and Management (10 papers) and Autoimmune and Inflammatory Disorders (8 papers). The work is most often cited by research in Genetics (2.6k citations), Immunology (1.8k citations) and Gastroenterology (333 citations). Taku Kobayashi has collaborated with scholars based in Japan, United States and Canada. Frequent co-authors include Toshifumi Hibi∥, Silvio Danese, Laurent Peyrin‐Biroulet, Tadakazu Hisamatsu, Britta Siegmund, Bo Shen, Catherine Le Berre, Charles N. Bernstein, Shu‐Chen Wei and Marc Ferrante. Their work appears in journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Investigation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact